Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation and expansion study to evaluate the safety,
tolerability, PK, and biological activity of VT3989 administered once-daily in patients with
advanced pleural malignant mesothelioma and/or metastatic solid tumors that are resistant or
refractory to standard therapy or for which no effective standard therapy is available.